Oct 2026· Journal of Gastrointestinal Cancer· Vol 57· 0 citations· 31 references
Medicine
TL;DR
Fruquintinib is characterized by a higher proportion of early-onset and potentially unlabeled adverse events, highlighting the need for early and tailored safety monitoring in clinical practice.
Background Cachexia is a devastating metabolic syndrome that has a profound impact on survival rate and quality of life. Currently, there is still a scarcity of systematic evidence regarding drug-induced cachexia. This study aims to identify drugs associated with cachexia through the first large-scale pharmacovigilance...
Ling-Li Huang, Shu-Chen Dong, Quan-Li Zhang et al.· Frontiers in Pharmacology· 0 citations
Background Entrectinib is effective for ROS1-positive non-small cell lung cancer (NSCLC), but its postmarketing safety profile remains incompletely characterized outside clinical trials. We conducted a dual-database pharmacovigilance study to characterize real-world reporting patterns, identify cross-database replicate...
A retrospective pharmacovigilance study using FAERS data covering the period from 2004 Q1 to 2025 Q4 reveals a strong signal of haematological toxicity associated with antitumour agents, supporting enhanced routine monitoring to mitigate clinical risks.
Xing-Nong Xu, Lei Ma· Frontiers in Immunology· 0 citations
ABSTRACT Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 receptor, is widely used in immune-mediated diseases, yet its real-world safety in pediatric populations remains insufficiently characterized. This retrospective pharmacovigilance study analyzed adverse event (AE) reports from the U.S. Fo...
Gang Wu, Xue-Qing Ma, Bin Zhu et al.· Human Vaccines & Immunothera...· 0 citations
Signals were identified for both drug classes across multiple SOCs, with gastrointestinal and general disorders and administration site conditions most frequently reported, suggesting the usefulness of FAERS data mining in identifying signals.
Maria Jacob, Alisha Roy Edakkarote, Sriya Lingamagunta et al.· International Journal of Pha...· 0 citations
Eribulin is used to treat metastatic breast cancer, but its adverse event (AE) profile requires comprehensive analysis using FDA Adverse Event Reporting System (FAERS) data to guide clinical use. We analyzed eribulin-related AE reports in FAERS (Q1 2011 - Q2 2024). Disproportionality analyses (ROR, PRR, MGPS, BCPNN) id...
Yao Zhou, Jie Gong, Le-Le Shen et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.